The Challenge of Treating Fatigue in Multiple Sclerosis: Anthony Feinstein, MPhil, PhD, FRCP


The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]

WATCH TIME: 4 minutes

"There is no hard evidence to suggest that any of these medications are more effective than placebo, which is disappointing for patients with MS because they're looking for a tablet that might be able to help them."

In patients with multiple sclerosis (MS), fatigue is the most commonly reported symptom, and is known as one of the most debilitating symptoms of the disease. Despite the high prevalence and significant impact of fatigue in MS, the symptom remains understudied because of its complexity and subjective nature.1 Over the years, research from specialists in neurology has opened the door to understanding the potential causes, impact, and treatment of MS-related fatigue. As an approach to treating fatigue, both pharmacological and nonpharmacological interventions are used in combination, encompassing a multi-disciplinary approach, in the current clinical practice.

Research shows that nonpharmacological interventions show a stronger and more significant favorable impact on reducing the impact or severity of fatigue compared with commonly prescribed pharmacological therapies. According to a prior review published in Frontiers in Neurology, findings suggest that nonpharmacological approaches used in isolation or in combination with pharmacological agents should be the mainstay of management of fatigue in patients with MS.2

Anthony Feinstein, MPhil, PhD, FRCP, a professor of psychiatry at the University of Toronto, presented on the management of fatigue in MS in a session at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 29 to June 1, in Nashville, Tennessee. At the meeting, Feinstein sat down in an interview with NeurologyLive® to discuss the common secondary causes of fatigue that should be ruled out before treating primary fatigue in patients with MS. He also talked about how cognitive behavioral therapy compares with pharmacologic medications in managing fatigue in MS based on recently published research. Furthermore, he spoke about the potential benefits and limitations of using mindfulness therapy for fatigue in MS.

Click here for more coverage of CMSC 2024.

1. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061-1067. doi:10.1093/sleep/33.8.1061
2. Khan F, Amatya B, Galea M. Management of fatigue in persons with multiple sclerosis. Front Neurol. 2014;5:177. Published 2014 Sep 15. doi:10.3389/fneur.2014.00177
Related Videos
Charbel Moussa, MBBS, PhD
Kelly Papesh, DNP, APRN, FNP-BC
Anvi Gadani, MD
David Shprecher, DO, MSci, FAAN
Jessica Ailani, MD
Video 2 - 4 KOLs are feature in, "Changes in Presentation of Spasticity Over Time"
Video 1 - 4 KOLs are feature in, "Definition and Pathophysiology of Spasticity"
Dolores D. Santamaria, MD
© 2024 MJH Life Sciences

All rights reserved.